From: Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma
Factor | Median Overall survival (months) | p -value in univariate analysis | p -value in multivariate analysis |
---|---|---|---|
Sex | Â | 0.96 | - |
Male | 50 | Â | Â |
Female | 55.9 | Â | Â |
HBeAg | Â | Â | - |
+ | NA | 0.39 | Â |
- | 55.9 | Â | Â |
Staging | Â | 0.001 | < 0.001 |
I | 13 | Â | Â |
II | 21 | Â | Â |
III | 23 | Â | Â |
IV | 24 | Â | Â |
B symptom | Â | 0.2 | - |
Yes | NA | Â | Â |
No | 55.9 | Â | Â |
Age(years) | Â | 0.21 | - |
> 60 | NA | Â | Â |
≤ 60 | 55.9 |  |  |
LDH | Â | 0.17 | - |
> normal | 46.7 | Â | Â |
normal | 55.9 | Â | Â |
Extranodal sites | Â | 0.47 | - |
> 1 | 37.5 | Â | Â |
0–1 | 55.9 |  |  |
PS | Â | 0.23 | - |
0–1 | 55.8 |  |  |
2–4 | NA |  |  |
Radiation therapy | Â | 0.004 | 0.093 |
Yes | NA | Â | Â |
No | 46.7 | Â | Â |
Pre-CT hepatic dysfunction | Â | 0.66 | - |
Yes | NA | Â | Â |
No | 55.9 | Â | Â |
Intra-CT hepatic dysfunction | Â | 0.016 | 0.02 |
Yes | 46.7 | Â | Â |
No | NA | Â | Â |
Rituximab | Â | 0.5 | - |
Yes | NA | Â | Â |
No | 55.9 | Â | Â |